Loading clinical trials...

Add-on Diuretics in Acute Decompensated Heart Failure | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Add-on Diuretics in Acute Decompensated Heart Failure

Clinical Study Comparing Empagliflozin, Acetazolamide, and Metolazone as Add-on Therapies to Loop Diuretics in Acute Decompensated Heart Failure

NCT07372040•Tanta University

View on ClinicalTrials.gov

Summary

The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female patients older than 18 years.
•2. Hospital admission with clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography).

Exclusion Criteria

•1. Type 1 diabetes.
•2. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<30 mL/min per 1.73 m² or end-stage kidney failure with the need for chronic dialysis treatment.
•3. A systolic blood pressure of less than 90 mmHg.
•4. Cardiogenic shock.
•5. Receipt of acetazolamide maintenance therapy.
•6. Receipt of an SGLT2 inhibitor, thiazide, or thiazide-like diuretic in the 48 hrs before randomization.
•7. Any cause of heart failure leading to decompensation that will need urgent management (eg, acute coronary syndrome, unstable arrhythmias, acute pulmonary embolism).
•8. Pregnant or breastfeeding women.
•9. Moderate to severe anemia.

Locations (1)

Tanta university

Tanta, Egypt

Key Dates

Start Date

February 1, 2026

Primary Completion Date

February 1, 2027

Completion Date

February 1, 2027

Last Updated

February 4, 2026

Enrollment

ESTIMATED participants

Conditions

Acute Decompensated Heart Failure

Interventions

empagliflozin

DRUG

Acetazolamide

DRUG

metolazone

DRUG

Contacts

Dalia A Gomaa, MSc in clinical pharmacy

CONTACT

+20+01063410525 dalia_gomaa@pharm.tanta.edu.eg

Dalia R El-Afify, Associate professor

CONTACT

+20+01006831093 dalia.mohamed1@pharm.tanta.edu.eg

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515

Acute Decompensated Heart Failure

View study

RECRUITINGNA

Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure

NCT07199088

Acute Decompensated Heart FailureHeart Failure, Diastolic+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Add-on Diuretics in Acute Decompensated Heart Failure

Inclusion Criteria

Exclusion Criteria

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure

EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF

Adherence to Medication in Patients With Acute Decompensated Heart Failure

Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study

Comparison of the Effectiveness of Different Diuretic Therapies in the Management of Acute Heart Failure